Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis
NCT06928246Phase 1Active, not recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of neuronox in atopic dermatitis (AD) (2 arms). Primary endpoints: Eczema Area and Severity Index at Day 28 and Physician Global Assessment at Day 28. Started Jul 2025; status: active, not recruiting.
02
Drugs
neuronox
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06928246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928246.